Research Analysts Issue Forecasts for DBV Technologies S.A.’s Q2 2023 Earnings (NASDAQ:DBVT)

DBV Technologies S.A. (NASDAQ:DBVTGet Rating) – Analysts at HC Wainwright reduced their Q2 2023 earnings per share (EPS) estimates for DBV Technologies in a research report issued to clients and investors on Tuesday, May 9th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings of ($0.13) per share for the quarter, down from their previous forecast of ($0.12). HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for DBV Technologies’ current full-year earnings is ($0.97) per share. HC Wainwright also issued estimates for DBV Technologies’ Q3 2023 earnings at ($0.13) EPS, Q4 2023 earnings at ($0.14) EPS, Q4 2023 earnings at ($0.14) EPS, FY2023 earnings at ($0.51) EPS, FY2024 earnings at ($0.47) EPS and FY2025 earnings at ($0.07) EPS.

DBV Technologies (NASDAQ:DBVTGet Rating) last issued its earnings results on Thursday, March 2nd. The company reported ($0.23) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.23). DBV Technologies had a negative return on equity of 48.25% and a negative net margin of 778.60%. The company had revenue of ($1.30) million during the quarter, compared to analysts’ expectations of $2.10 million.

Several other equities research analysts also recently weighed in on the company. JMP Securities reaffirmed a “market outperform” rating and issued a $4.00 target price on shares of DBV Technologies in a research report on Friday, March 3rd. assumed coverage on DBV Technologies in a research report on Tuesday. They issued a “sell” rating for the company. Two analysts have rated the stock with a sell rating and four have assigned a buy rating to the stock. Based on data from, DBV Technologies has an average rating of “Hold” and a consensus target price of $6.67.

DBV Technologies Trading Up 12.1 %

NASDAQ:DBVT opened at $1.85 on Thursday. The firm has a market cap of $348.31 million, a P/E ratio of -3.03 and a beta of 1.27. The stock’s 50 day simple moving average is $1.62 and its 200-day simple moving average is $1.49. DBV Technologies has a 12-month low of $1.08 and a 12-month high of $3.43.

Institutional Investors Weigh In On DBV Technologies

A number of large investors have recently modified their holdings of DBVT. Braidwell LP acquired a new position in shares of DBV Technologies in the 4th quarter valued at about $18,525,000. VR Adviser LLC bought a new position in DBV Technologies during the fourth quarter valued at $29,258,000. Fairmount Funds Management LLC lifted its position in shares of DBV Technologies by 46.2% during the third quarter. Fairmount Funds Management LLC now owns 7,064,964 shares of the company’s stock worth $12,505,000 after acquiring an additional 2,233,809 shares in the last quarter. RA Capital Management L.P. purchased a new stake in shares of DBV Technologies in the third quarter worth $6,593,000. Finally, Vivo Capital LLC purchased a new stake in DBV Technologies during the third quarter valued at about $4,795,000. Institutional investors and hedge funds own 18.37% of the company’s stock.

DBV Technologies Company Profile

(Get Rating)

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients.

Featured Articles

Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with's FREE daily email newsletter.